Inventiva completes a capital increase of € 8.2 million subscribed by leading US and European biotech investors

    NEXT STORY
    AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
    PREV STORY
    Annual Financial Report
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Updated Phase 1 Data Show Bavarian Nordic’s Vaccine Candidate Induces a Broad and Durable Immune Response against RSV

    Antibody levels maintained against multiple targets 6 months post vaccinationAdditional T cell data confirms ...

    author_avatar
    NASDAQ Market News

    Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting

    HAMPTON, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today ...

    author_avatar
    NASDAQ Market News

    Evelo Biosciences to Present Preclinical Data from its EDP1503 Oncology Program at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting

    author_avatar
    NASDAQ Market News